wound management technologies, inc., through its subsidiary, wound care innovations, llc, distributes collagen-based wound care products in the united states. the company holds worldwide license to certain technologies and processes related to a collagen-based wound care product formulation under the brand name celleraterx. it markets celleraterx for pressure ulcers, diabetic ulcers, surgical wounds, ulcers due to arterial insufficiency, traumatic wounds, first and second degree burns, and superficial wounds. the company offers celleraterx in gel and powder forms. it serves healthcare providers, such as physicians, clinics, and hospitals. wound management technologies was formerly known as mb software corporation. the company was founded in 1982 and is based in fort worth, texas.
Company profile
Ticker
SMTI
Exchange
Website
CEO
J. Michael Carmena
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
INAV TRAVEL CORPORATION, MB SOFTWARE CORP, WOUND MANAGEMENT TECHNOLOGIES, INC.
SEC CIK
Corporate docs
Subsidiaries
Cellerate, LLC • Wound Care Innovations, LLC • Sanara Biologics, LLC • Rochal Technologies, LLC • United Wound and Skin Solutions, LLC • Precision Healing, LLC • Pixalere Healthcare USA, LLC • Scendia Biologics, LLC • Sanara MedTech Applied Technologies, LLC • Sanara Collagen Peptides, LLC ...
IRS number
592220004
SMTI stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
3 Jun 24
8-K
Departure of Directors or Certain Officers
30 May 24
S-3
Shelf registration
21 May 24
DEFA14A
Additional proxy soliciting materials
15 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Sanara MedTech Inc. Announces First Quarter 2024 Results
13 May 24
8-K
Sanara MedTech Inc. Announces $55 Million Debt Facility
18 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
Transcripts
SMTI
Earnings call transcript
2023 Q4
26 Mar 24
SMTI
Earnings call transcript
2023 Q3
14 Nov 23
SMTI
Earnings call transcript
2023 Q2
15 Aug 23
SMTI
Earnings call transcript
2023 Q2
15 Aug 23
SMTI
Earnings call transcript
2023 Q1
16 May 23
SMTI
Earnings call transcript
2022 Q4
21 Mar 23
SMTI
Earnings call transcript
2022 Q3
15 Nov 22
SMTI
Earnings call transcript
2022 Q2
16 Aug 22
SMTI
Earnings call transcript
2022 Q1
17 May 22
SMTI
Earnings call transcript
2021 Q4
31 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.83 mm | 2.83 mm | 2.83 mm | 2.83 mm | 2.83 mm | 2.83 mm |
Cash burn (monthly) | 772.99 k | 371.52 k | 510.57 k | 396.27 k | 531.46 k | 258.22 k |
Cash used (since last report) | 1.68 mm | 805.45 k | 1.11 mm | 859.12 k | 1.15 mm | 559.82 k |
Cash remaining | 1.15 mm | 2.02 mm | 1.72 mm | 1.97 mm | 1.68 mm | 2.27 mm |
Runway (months of cash) | 1.5 | 5.4 | 3.4 | 5.0 | 3.2 | 8.8 |
Institutional ownership, Q4 2023
0.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 42 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 460.73 mm |
Total shares | 11.21 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Salem Investment Counselors | 11.21 k | $460.73 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Jacob A. Waldrop | Common Stock | Grant | Acquire A | No | No | 0 | 3,101 | 0.00 | 3,101 |
7 Mar 24 | Fleming Zachary B. | Common Stock | Grant | Acquire A | No | No | 0 | 12,693 | 0.00 | 48,854 |
7 Mar 24 | Michael D. McNeil | Common Stock | Grant | Acquire A | No | No | 0 | 4,650 | 0.00 | 25,998 |
1 Mar 24 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 38.96 | 599 | 23.34 k | 21,348 |
1 Mar 24 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 38.96 | 687 | 26.77 k | 21,947 |
News
Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $44 Price Target
15 May 24
Sanara MedTech Q1 EPS $(0.21) Misses $(0.07) Estimate, Sales $18.54M Beat $18.50M Estimate
13 May 24
Cantor Fitzgerald Maintains Overweight on Sanara MedTech, Lowers Price Target to $44
27 Mar 24
Sanara MedTech Q4 EPS $(0.03) Beats $(0.13) Estimate, Sales $17.69M Beat $16.50M Estimate
25 Mar 24
Earnings Scheduled For March 25, 2024
25 Mar 24
Press releases
Sanara MedTech Inc. Announces First Quarter 2024 Results
13 May 24
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
29 Apr 24
Sanara MedTech Inc. Announces $55 Million Debt Facility
18 Apr 24
Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer
5 Apr 24
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates
13 Mar 24